Itraconazole Bioassay

Set Up an Account. Download a Test Menu. Start Ordering Tests.

Get Started →

Test Code

312
Clinical Significance

The MVista® Itraconazole bioassay test aids in monitoring antifungal therapy.
Methodology

Bioassay
Limitations
The result is not intended to be used as the sole means for clinical diagnosis or patient management decisions.
- – The bioassay is not accurate if the patient has taken another antifungal agent concurrently or within the prior week.
- – Concentration determined on a single specimen may not reflect future concentrations because of changes in adherence, drug dosage, route of administration, absorption, or receipt of other medication affecting absorption or metabolism of the azole.
Specimen Collection
- Serum: Collect serum specimens in serum separator or red top tube. Allow blood to clot for 30 minutes, then centrifuge. Pipette serum into a plastic screw cap vial.
- Plasma: Collect plasma specimens in an EDTA or heparin tube. Centrifuge for 15 minutes and pipette plasma into a plastic screw cap vial.
Minimum Specimen Requirements

Serum/Plasma: 0.25 mL
Specimen Stability

Room Temperature/Refrigerated/Frozen: 7 days
Specimen Rejection

Any specimen type other than serum or plasma.
Transport Temprature

Refrigerated/Frozen
Shipping

Ship on dry ice or frozen cool pack for next day service. Monday – Friday delivery.
Turnaround Time

Testing performed on Wednesday. Results released the next morning.

Serum/Plasma: 2 days
Reference Range

Therapeutic ranges have not been established, but levels of at least 3.0 µg/mL have been recommended for treatment. Lower concentrations (1 – 2.9 µg/mL) may be sufficient for treatment depending on the MIC of the organism.
Interpretative Information
- None Detected: Reported when there is no zone of inhibition.
- <0.3 µg/mL: Reported when the zone of inhibition is smaller than that of the lowest calibrator.
- Positive: 0.3 – 20.0 µg/mL
- >20.0 µg/mL: Reported when the zone of inhibition is greater than the highest calibrator.
Additional Information
- – Follow-up testing may be necessary if there are changes in treatment, including starting or stopping interacting medications, or suspicion of treatment failure.
- – Drug levels should be measured after treatment, of at least 2 weeks in dogs and 3 weeks in cats, to reach a steady state.
- – Preferable to collect blood sample at trough time.